Eterna Therapeutics is a preclinical-stage biopharmaceutical company focusing on realizing the potential of mRNA cell engineering to provide patients with new medicines. Co. has in-licensed a portfolio of over 100 patents covering primary mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system. Co. has a cell line customization and license agreement with Lineage Cell Therapeutics, Inc. (Lineage), pursuant to which, Lineage may request that Co. develops for, and deliver to, Lineage certain induced pluripotent stem cell lines. The ERNA YTD return is shown above.
The YTD Return on the ERNA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ERNA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ERNA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|